Table 3. Association between APEX1 Asp148Glu polymorphism and three main indexes about the Pca development (GS, clinical status and PSA level).

Index	Race	Model	OR	95% CI	I2	P
GS	Asian Descent	Dominant model (GG+GT vs TT)	1.169	0.745, 1.834	35.80%	0.212	Jing et al., Mandal et al.
GS	Asian Descent	Recessive model (GG vs GT+TT)	1.078	0.644, 1.807	31.70%	0.226
GS	Asian Descent	Codominant model (GG vs GT)	0.898	0.265, 3.049	70.40%	0.066
GS	Asian Descent	Codominant model (GG vs TT)	0.876	0.454, 1.691	0.00%	0.704
GS	Asian Descent	Per-allele analysis (G vs T)	1.109	0.811, 1.517	0.00%	0.784
GS	Mix Descents	*Dominant model (GG+GT vs TT)	1.164	0.811, 1.669	0.00%	0.459	Jing et al., Mandal et al., Kuasne et al.
clinical status	Asian Descent	Dominant model (GG+GT vs TT)	1.06	0.303, 3.712	87.40%	0.005	Jing et al., Mandal et al.
clinical status	Asian Descent	Recessive model (GG vs GT+TT)	1.53	0.911, 2.569	0.00%	0.593
clinical status	Asian Descent	Codominant model (GG vs GT)	1.335	0.737, 2.418	0.00%	0.658
clinical status	Asian Descent	Codominant model (GG vs TT)	1.747	0.955, 3.195	40.60%	0.194
clinical status	Asian Descent	Per-allele analysis (G vs T)	1.109	0.469, 2.625	86.30%	0.007
clinical status	Mix Descents	*Dominant model (GG+GT vs TT)	0.903	0.416, 1.963	78.30%	0.01	Jing et al., Mandal et al., Kuasne et al.
PSA	Mix Descents	*Dominant model (GG+GT vs TT)	0.897	0.560, 1.437	0.00%	0.62	Jing et al., Kuasne et al.

* The results of “*Dominant model (GG+GT vs TT)” contained three sets of data (reference 8, 20, 22) with mix races.

* GS: Gleason score; PSA: prostate-specific antigen

* GS groups: the high vs. low Gleason score (Gleason≥7 versus Gleason <7)

* Clinical status groups: case: Advanced or Metastasis (+) or clinical stages≥T3; control: Localized or Metastasis (−) or clinical stages<T3

* PSA group modeled as a categorical variable. The threshold was 10ng/ml (PSA case: PSA>10 ng/mL, PSA control: PSA≤10 ng/mL)